reference/31192854

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/31192854

Outgoing Links

Predicate	Object
contentType	Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
endingPage	64.e8
issn	1078-1439
issueIdentifier	2
pageRange	64.e1-64.e8
publicationName	Urologic Oncology: Seminars and Original Investigations
startingPage	64.e1
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_803892ae1b5439a407ed1ca2da48ced7 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_6f6d8aa339ed72296a2e261f2a7299d7
bibliographicCitation	Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, Noro D, Tanaka T, Ito H, Okuyama Y, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Aoki M, Ohyama C. Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study. Urologic Oncology: Seminars and Original Investigations. 2022 Feb;40(2):64.e1–8. doi: 10.1016/j.urolonc.2021.11.005.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_32fb8f80a05abf486bc276648c711cd0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0026-4079 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b01cff5a9a5d8f5a68cfa80ae96c9ad0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3fedfb93052899d18a1e5fa7aea706e0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9450-0027 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b8b141bc3a2fa74bee2e2a9e5d8842e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8b7a1390793233c3f7fbf9ca3561e869 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4ec4bb2f09e4a57122dd0fd6f88bb61c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9e3ee06bfde18db75eb0551e7610de4f http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3760-919X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e43f2478594b6fc2d1b96346b6c6f4ac http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b158abaab6e4e30757026bf6246494a6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d4c2a598456f5e7b25e44056ec5ab5a http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7104-0945 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ca07a4674f4864a703e55ea92c47ca7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8187-7212
date	202202
identifier	https://pubmed.ncbi.nlm.nih.gov/34973857 https://doi.org/10.1016/j.urolonc.2021.11.005
isPartOf	https://portal.issn.org/resource/ISSN/1078-1439 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21529
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study
discusses	http://id.nlm.nih.gov/mesh/M000627680 http://id.nlm.nih.gov/mesh/M0018449
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D064129Q000188 http://id.nlm.nih.gov/mesh/D011883Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D012189 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D011883Q000494 http://id.nlm.nih.gov/mesh/D008297
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6335825 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fce276cc0efd2412c7dafdbb1e82fcc8 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.4.21.77

Showing number of triples: 1 to 50 of 50.